A novel, fixed-duration drug combination -; consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 inhibitor (venetoclax), with or without a third blood cancer drug -; shows deep and durable responses in patients with chronic lymphocytic leukemia (CLL), Dana-Farber Cancer Institute investigator Jennifer Brown, MD, PhD, reports at the 66th American Society for Hematology (ASH) Annual Meeting and Exposition, on behalf of the trial investigators.